References

Abdel-Razeq, H., Edaily, S., Iweir, S., Salam, M., Seleh, Y., Sughayer, M., . . . Taqash, A. (2020). Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer. Retrieved from https://doi-org.misericordia.idm.oclc.org/10.1007/s10549-020-05942-6

Clinical Affiliate Site. (2022). Mammogram[X-ray Image]. Retrieved from Clinical Affiliate Site.

Clinical Affiliate Site. (2022). Ultrasound[Ultrasound Image]. Retrieved from Clinical Affiliate Site.

Eisenberg, R. L., & Johnson, N. M. (2021). *Comprehensive radiographic pathology* (7th ed.). St. Louis, MO: Elsevier.

Elsers, D. A., Mostafa Masoud, E., Kamel, N. A., & Ahmed, A. M. (2021). Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new? *Annals of Diagnostic Pathology,* *55.* Retrieved from https://doi.org/10.1016/j.anndiagpath.2021.151831

Goshen Health (2022). Triple-positive breast cancer: HER2 positive breast cancer. Retrieved from https://goshenhealth.com/health-library/triple-positive-breast-cancer

Ma, D., Yang, Q., Yin, K., Shi, P., Chen, X., Dong, T., . . . Tian, X. (2023). Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer-A retrospective study. *Frontiers in Oncology,* *12*. Retrieved from https://www.frontiersin.org/articles/10.3389/fonc.2022.999894/full

Zeng, J., Edelweiss, M., Ross, D. S., Xu, B., Moo, T., Brogi, E., & D'Alfonso, T. M. (2020). Triple-positive breast carcinoma: Histopathologic features and response to neoadjuvant chemotherapy. *Archives of Pathology & Laboratory Medicine,* *145*(6), 728-735. Retrieved from https://doi.org/10.5858/arpa.2020-0293-OA